This collection of articles and expert perspectives explores the critical challenges shaping ADC development today, from analytical strategy and impurity control to linker technology innovations and evolving regulatory standards. It also examines the collaborative expertise needed to bring these transformative therapies to patients. The post Analytical Challenges for Antibody-Drug Conjugate (ADC) Manufacturing appeared first on GEN – Genetic Engineering and…
You may also like
SMC recommends VEOZA for moderate to severe menopausal...
SMC backs Columvi combination for second-line lymphoma...
Bristol Myers Squibb’s New Drug Application for...
Exonate appoints Olav Hellebø as CEO
Genetic Map Opens Door to Development of New Therapies...
StockWatch: Insilico Projects Profit, Revenue Leaps as...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.